Planet Fitness Q4 revenue rises 53% to $281.3 mln, above the FactSet consensus $271.5 mln
6:32 am ET February 23, 2023 (MarketWatch) Print
(END) Dow Jones Newswires
February 23, 2023 06:32 ET (11:32 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Regenxbio IncChange company Symbol lookupSelect an option...RGNX Regenxbio IncOGSYS Otis Gallery LLCRDN Radian Group IncSLNO Soleno Therapeutics IncREI Ring Energy IncFSHOX Fidelity® Select Construction & Housing PortfolioNNN NNN REIT IncUTHR United Therapeutics CorpKEX Kirby CorpDDOG Datadog IncGo
Change company Symbol lookup
Select an option...
RGNX Regenxbio Inc
OGSYS Otis Gallery LLC
RDN Radian Group Inc
SLNO Soleno Therapeutics Inc
REI Ring Energy Inc
FSHOX Fidelity® Select Construction & Housing Portfolio
NNN NNN REIT Inc
UTHR United Therapeutics Corp
KEX Kirby Corp
DDOG Datadog Inc
Health Care : Biotechnology | Small Cap Blend
Company profileREGENXBIO Inc. is a clinical-stage biotechnology company, which is focused on providing curative potential of gene therapy. Its investigational gene therapies are designed to deliver functional genes to address genetic defects in cells. The Company’s investigational AAV Therapeutics include RGX-314, RGX-202, RGX-121, RGX-111 and RGX-181 and RGX-381. RGX-314 is meant for the treatment of large patient populations impacted by wet age-related macular degeneration (wet AMD), diabetic retinopathy and other chronic retinal diseases. RGX-202 is developed to treat Duchenne muscular dystrophy, one of the common fatal genetic disorders affecting children. RGX-121, RGX-111 and RGX-181 are developed to treat Mucopolysaccharidosis type II, Mucopolysaccharidosis type I, and late infantile neuronal ceroid lipofuscinosis type II (CLN2 disease), all of which are progressive, neurodegenerative lysosomal storage disorders. RGX-381 is developed to treat the ocular manifestations of CLN2 disease.
|
|
|
|
| |
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
Information and news provided by ,, , Computrade Systems, Inc., ,, and
Copyright © 2023. All rights reserved.